{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:01:31Z","timestamp":1772118091872,"version":"3.50.1"},"reference-count":38,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s267405","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T20:56:51Z","timestamp":1615237011000},"page":"1045-1053","source":"Crossref","is-referenced-by-count":13,"title":["An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-0250","authenticated-orcid":true,"given":"Daniel","family":"G Oliveira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2956-1966","authenticated-orcid":true,"given":"Raquel","family":"Faria","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":true,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2021,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2165\/11591580-000000000-00000","volume":"30","author":"Raho","year":"2012","journal-title":"PharmacoEconomics"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2013-204934","volume":"73","author":"Orr","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","volume":"33","author":"Reis","year":"2019","journal-title":"BioDrugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","volume":"14","author":"Taams","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clinic Rev Allerg Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/annrheumdis-2018-214138","volume":"78","author":"Wade","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/art.38376","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clim.2017.03.016","volume":"183","author":"Chowdhury","year":"2017","journal-title":"Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/jid.2008.294","volume":"129","author":"Watanabe","year":"2009","journal-title":"J Clin Investig Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e001306","DOI":"10.1136\/rmdopen-2020-001306","volume":"6","author":"Shah","year":"2020","journal-title":"RMD Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/eji.201948138","volume":"50","author":"Burns","year":"2020","journal-title":"Eur J Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2020.02.004","volume":"52","author":"Goepfert","year":"2020","journal-title":"Immunity"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/bcp.13185","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"ref24","unstructured":"Deodhar A, Gossec L, Mease PJ, et al. Bimekizumab treatment is associated with improvements in back pain and fatigue in patients with active psoriatic arthritis: 48-week results from a Phase 2b study. ACR Meeting Abstracts [Internet]; [cited January 3, 2021]. Available from: https:\/\/acrabstracts.org\/abstract\/bimekizumab-treatment-is-associated-with-improvements-in-back-pain-and-fatigue-in-patients-with-active-psoriatic-arthritis-48-week-results-from-a-phase-2b-study\/. Accessed February 25, 2021."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1136\/annrheumdis-2020-eular.4204","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref26","unstructured":"Gossec L, Mease P, Gottlieb A, et al. Bimekizumab improves patient-reported outcomes in psoriatic arthritis: 48-week results from a phase 2b study and association between patient-reported outcomes and disease activity. ACR Meeting Abstracts [Internet]; [cited January 3, 2021]. Available from: https:\/\/acrabstracts.org\/abstract\/bimekizumab-improves-patient-reported-outcomes-in-psoriatic-arthritis-48-week-results-from-a-phase-2b-study-and-association-between-patient-reported-outcomes-and-disease-activity\/. Accessed February 25, 2021."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/annrheumdis-2020-eular.1850","volume":"79","author":"Mcinnes","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref28","unstructured":"Merola J, Behrens F, Kivitz A, et al. Bimekizumab maintenance of response in patients with psoriatic arthritis: 2-year results from a Phase 2b dose-ranging study and its open-label extension. ACR Meeting Abstracts [Internet]; [cited January 3, 2021]. Available from: https:\/\/acrabstracts.org\/abstract\/bimekizumab-maintenance-of-response-in-patients-with-psoriatic-arthritis-2-year-results-from-a-phase-2b-dose-ranging-study-and-its-open-label-extension\/. Accessed February 25, 2021."},{"key":"ref29","unstructured":"Benfaremo D, Paci V, Luchetti MM, Gabrielli A. Novel therapeutic approaches and treatment targets for psoriatic arthritis. CPB [Internet]; September 28, 2020 [cited January 3, 2021]:21. Available from: https:\/\/www.eurekaselect.com\/186326\/article. Accessed February 25, 2021."},{"key":"ref30","unstructured":"COSENTYX (secukinumab) injection, Label changes, FDA [Internet]; [cited January 1, 2021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125504s001s002lbl.pdf. Accessed February 25, 2021"},{"key":"ref31","unstructured":"TALTZ (ixekizumab) injection, SC, Label changes, FDA [Internet]; [cited January 1, 2021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125521s004lbl.pdf. Accessed February 25, 2021."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e34959","DOI":"10.1371\/journal.pone.0034959","volume":"7","author":"Tong","year":"2012","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cyto.2015.09.011","volume":"89","author":"Qian","year":"2017","journal-title":"Cytokine"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"s15","DOI":"10.25251\/skin.5.supp.15","volume":"5","author":"Warren","year":"2021","journal-title":"J Skin"},{"key":"ref38","unstructured":"UCB Press Release \u2013 Bimekizumab superior to Cosentix in achieving complete psoriasis skin clearance [Internet]; [cited January 1, 2020]. Available from: https:\/\/www.ucb.com\/_up\/ucb_com_presscenter\/documents\/b611cc6eeb06894e.pdf. Accessed February 25, 2021"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=67491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=67491","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T20:57:01Z","timestamp":1615237021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/an-overview-of-bimekizumab-for-the-treatment-of-psoriatic-arthritis-th-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2147\/dddt.s267405","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}